A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar 100 microg bd delivered via a metered dose inhaler (MDI) (TEVA UK Ltd) with a reference beclometasone formulation via a reference MDI in children with mild to moderate asthma.

Trial Profile

A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar 100 microg bd delivered via a metered dose inhaler (MDI) (TEVA UK Ltd) with a reference beclometasone formulation via a reference MDI in children with mild to moderate asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2013

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 28 Jul 2011 New trial record
    • 22 Jul 2011 Results published in Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top